CN103966339B - 长链非编码rna crnde的应用方法 - Google Patents
长链非编码rna crnde的应用方法 Download PDFInfo
- Publication number
- CN103966339B CN103966339B CN201410225220.4A CN201410225220A CN103966339B CN 103966339 B CN103966339 B CN 103966339B CN 201410225220 A CN201410225220 A CN 201410225220A CN 103966339 B CN103966339 B CN 103966339B
- Authority
- CN
- China
- Prior art keywords
- lncrnacrnde
- patients
- gliomas
- prognosis
- crnde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 9
- 108091027963 non-coding RNA Proteins 0.000 title abstract description 7
- 102000042567 non-coding RNA Human genes 0.000 title abstract description 7
- 206010018338 Glioma Diseases 0.000 claims abstract description 49
- 238000004393 prognosis Methods 0.000 claims abstract description 25
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 15
- 238000003753 real-time PCR Methods 0.000 claims abstract description 15
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 238000010839 reverse transcription Methods 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 5
- 108091026822 U6 spliceosomal RNA Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001701 chloroform Drugs 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 229940048102 triphosphoric acid Drugs 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 3
- 238000011529 RT qPCR Methods 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 11
- 108091046869 Telomeric non-coding RNA Proteins 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 5
- 238000010837 poor prognosis Methods 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 3
- 108020005198 Long Noncoding RNA Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091007417 HOX transcript antisense RNA Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 206010061311 nervous system neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种长链非编码RNA(long?no-coding?RNA,LncRNA)CRNDE的应用方法,即用于制备胶质瘤患者的预后制剂,特别是制备出实时荧光定量分析法预测胶质瘤患者预后的试剂盒。通过研究证实LncRNA?CRNDE在胶质瘤组织中表达上调,高表达LncRNA?CRNDE的胶质瘤患者比低表达LncRNA?CRNDE的胶质瘤患者预后差,因此,将Lnc?RNA?CRNDE的表达用于胶质瘤患者的预后预测,可以为预测胶质瘤患者的预后提供强有力的分子生物学依据,具有深远的临床意义和推广性。
Description
技术领域
本发明属于肿瘤分子生物学领域,具体涉及LncRNACRNDE在制备胶质瘤患者预后试剂中的应用方法。
背景技术
胶质瘤约占神经系统肿瘤的40.49%,是最常见的肿瘤之一,目前采用的治疗手段包括手术治疗联合化疗和放疗,尤为手术切出效果明显。但是胶质瘤病人的生存期仍无明显延长。据相关报道,胶质瘤病人的5年生存率低于25%。目前,对胶质瘤的预后判定没有金标准,也没有特异性指标,远远不能适应对胶质瘤进行预后判定的需求。因此,对人胶质瘤进行预后判定,以便选择最佳治疗方案,显著提高患者生存率,成为神经外科领域亟待解决的重要课题。
lncRNA是一类转录本长度大于200bp的非编码RNA,具有相对较长的核苷酸链,其分子内部具有特定的二级空间结构,能提供与蛋白质结合的多个位点,或与DNA、RNA之间通过碱基互补配对原则发生特异性、动态性相互作用。近年来,lncRNA作为一类重要的调控分子及其在临床诊断、化疗敏感性和预后评价等方面的应用价值,已经逐渐得到研究者的重视。有研究表明HOTAIR在原发乳腺肿瘤和转移瘤中的表达都会增加,原发肿瘤中HOTAIR的表达水平可以用来有效预测癌转移和死亡。lncRNAPCA3在前列腺癌中高度过表达,这种lncRNA是在尿液中发现的,相当便于临床检测。由此可见,lncRNA作为诊断、预后和治疗的分子标志物具有巨大潜力。
发明内容
本发明的目的是提供一种LncRNACRNDE的应用方法,即LncRNACRNDE(colorectalneoplasiadifferentiallyexpressed)定位于染色体16q12.2,GeneBank登录号:NR_110452能作为胶质瘤预后的判断标准,用于制备胶质瘤患者的预后制剂,更进一步能够提供一种性价比高,易于推广应用的胶质瘤预后预测试剂盒。
长链非编码RNACRNDE的应用方法,所述的长链非编码RNACRNDE用于制备胶质瘤患者的预后制剂,该长链非编码RNACRNDE的序列见SEQNO:1。
所述的用于制备胶质瘤患者的预后制剂包括实时荧光定量PCR检测试剂。
所述的实时荧光定量PCR检测试剂包括进行实时荧光定量PCR的特异性引物:
LncRNACRNDE正向引物:5'-CTGCGTGACAACTGAGGA-3',
LncRNACRNDE反向引物5'-GTAGGATGCCACTGGAAAT-3。
所述的实时荧光定量PCR检测试剂为试剂盒,
该试剂盒包括:(1)从胶质瘤组织中抽提总RNA所用试剂,包括RNA稳定溶液、Trizol试剂、三氯甲烷、异丙醇、无酶水;(2)以总RNA为模板将LncRNACRNDE逆转录为cDNA所用试剂,包括逆转录缓冲液、三磷酸碱基脱氧核苷酸、RNA酶抑制剂、MMLV逆转录酶以及LncRNACRNDE所用随机引物;(3)将cDNA实时定量PCR所用试剂,包括LncRNACRNDE实时荧光定量PCR特异性引物、U6snRNA内参特异性PCR引物、实时荧光定量SYBR染料、无酶水;
LncRNACRNDE实时荧光定量PCR特异性引物
LncRNACRNDE正向引物5'-CTGCGTGACAACTGAGGA-3',
LncRNACRNDE反向引物5'-GTAGGATGCCACTGGAAAT-3。
U6snRNA内参特异性PCR引物:
正向引物为5′-ATTGGAACGATACAGAGAAGATT-3′,
反向引物为5′-GGAACGCTTCACGAATTTG-3′。
在前期研究工作中,申请人通过DIANA-LncBase软件分析与miR-101竞争性结合MRE序列的LncRNA时,发现了LncRNACRNDE。申请人在胶质瘤组织中提取RNA,逆转录后进行实时荧光定量PCR分析LncRNACRNDE的表达,发现:LncRNACRNDE在胶质瘤中表达上调,与正常人脑组织中的表达差异显著。且LncRNACRNDE表达水平不同的胶质瘤患者中预后存在明显差异,经Kaplan-Meier生存分析发现LncRNACRNDE高表达的胶质瘤患者生存率明显低于低表达的患者;多因素Cox比例风险模型的预后分析发现LncRNACRNDE的相对危险度>1,表明LncRNACRNDE高表达的患者预后较低表达的患者预后差,所以LncRNACRNDE的高表达是胶质瘤患者预后风险预测的独立危险因素。据此,申请人提出利用LncRNACRNDE制备用于胶质瘤患者预后的制剂。。
将LncRNACRNDE用于胶质瘤患者预后的检测方法:(1)收集待测个体术后切除的胶质瘤组织,抽提总RNA;(2)以总RNA为模板将CRNDE逆转录为cDNA;(3)用CRNDE特异性引物进行实时荧光定量PCR扩增,获得相对表达量2ΔΔCT,当2ΔΔCT>0.61342时提示CRNDE为高表达。
利用本发明的检测制剂可以检测LncRNACRNDE在胶质瘤患者中的表达水平,为胶质瘤患者预后预测提供了强有力的分子生物学基础,具有深远的临床意义和推广性。
附图说明
图1为实时荧光定量PCR分析LncRNACRNDE在胶质瘤组织与正常脑组织中的表达
差异;
图2为LncRNACRNDE与37例胶质瘤患者预后的关系。
具体实施方式
在前期研究工作中,申请人通过DIANA-LncBase软件分析与miR-101竞争性结合MRE序列的LncRNA时,发现了LncRNACRNDE。申请人在胶质瘤组织中提取RNA,逆转录后进行实时荧光定量PCR分析LncRNACRNDE的表达,发现:LncRNACRNDE在胶质瘤组织中表达上调,与正常人脑组织中的表达差异显著(P=0.017)(图1)。且LncRNACRNDE表达水平不同的胶质瘤患者中预后存在明显差异,经Kaplan-Meier生存分析发现LncRNACRNDE高表达的胶质瘤患者生存率明显低于低表达的患者(P=0.014)(图2),多因素Cox比例风险模型的预后分析发现LncRNACRNDE的相对危险度>1(RR=1.245),表明LncRNACRNDE高表达的患者预后较低表达的患者预后差,LncRNACRNDE的高表达是胶质瘤患者预后风险预测的独立危险因素。
实施例1制备LncRNACRNDE用于胶质瘤患者预后的试剂盒(50次反应)
1.RNA稳定溶液50ml
2.异丙醇100ml
3.三氯甲烷100ml
4.Trizol50ml
5.无酶水10ml
6.1μM随机逆转录引物50ul
7.5×逆转录缓冲液200ml
8.10mM三磷酸碱基脱氧核苷酸100ul
9.40U/μlRNA酶抑制剂500ul
10.200U/μlMMLV逆转录酶50ul
11.PremixExTaq50ul
12.10μMLncRNACRNDE特异性引物30ul
正向引物5'-CTGCGTGACAACTGAGGA-3'
反向引物5'-GTAGGATGCCACTGGAAAT-3'
13.10μMU6snRNA特异性引物30ul
正向引物为5'-ATTGGAACGATACAGAGAAGATT-3'
反向引物为5'-GGAACGCTTCACGAATTTG-3'。
实施例2胶质瘤组织中LncRNACRNDE的检测
1、胶质瘤组织的保存:收集待测胶质瘤组织存放于盛有RNA稳定溶液的冻存管中,放至-80℃冰箱备用。
2、组织中RNA的抽提:取适量标本于经180℃烘烤6-8h后的研钵中加入液氮研磨标本,研磨至粉末状后于研钵中加入1mlTrizol研钵标本,研磨成液体状后用移至tube管,加氯仿200μl/mlTrizol于Tube中,用手震荡15-30s,冰上放置5min,4℃12000g离心15min;小心取上层水相入新tube中,加入预冷的异丙醇0.5ml/mlTrizol混匀,-20℃冰箱静置20min,4℃12000g离心10min;弃上清,加入75%DEPC水稀释的乙醇1-2ml混匀,4℃7500g离心5min,尽量弃上清,室温干燥5-10min,加入DEPC水10-20μl溶解RNA。分光光度计测RNA的浓度及质量,OD260/280比值在1.8-2.0之间,-80℃保存。
3、LncRNACRNDE逆转录:使用Thermo公司的逆转录试剂盒。20μL逆转录反应的体系如下:
成分 | 剂量/管 |
随机逆转录引物(1μM) | 1μl |
RNA样本 | 2ug |
无酶水 | To12μl |
逆转录第一步条件:65℃5分钟
成分 | 剂量/管 |
5×逆转录缓冲液 | 4μl |
三磷酸碱基脱氧核苷酸(10mM) | 2μl3 --> |
RNA酶抑制剂(40U/μl) | 1μl |
MMLV逆转录酶(200U/μl) | 1μl |
第一步PCR的产物 | 12μg |
20μl |
逆转录第二步程序:25℃5分钟,42℃60分钟,70℃5分钟。
4、CRNDE特异性引物进行实时定量PCR:CRNDE特异性引物序列由上海生工生物工程有限公司合成。
先将逆转录产物稀释5倍,混匀。20μL反应体系如下:
成分 | 剂量/管 |
SYBR Premix Ex Taq | 10μl |
CRNDE特异性引物(10μM) | 0.5μl |
cDNA产物 | 1μl |
无酶水 | To20μl |
实时荧光定量PCR反应程序:95℃3分钟,40个循环,95℃10秒,60℃30秒。
LncRNACRNDE特异性引物序列为:
正向引物5'-CTGCGTGACAACTGAGGA-3',
反向引物5'-GTAGGATGCCACTGGAAAT-3。
5、-2ΔΔCT指标的测定:本实验数据采用相对定量的分析方法,U6作为内参基因,数据利用软件GraphPadPrism进行分析。分析发现,与LncRNACRNDE在正常脑组织中的表达相比,52例脑胶质瘤患者中LncRNACRNDE的表达明显上调,差异具有显著性(P=0.017)。
6、预后判断
通过对实验所采用的52例胶质瘤患者随访统计资料发现,15例患者在随访时由于手机停机或者换号或者其他原因联系不上,最后能联系上的胶质瘤患者或家属为37例,这37例患者或家属接受后续的随访分析。我们详细询问了这些患者或家属首次发病的时间,治疗情况,复发状况及死亡时间等,随访时间为1-46个月。在所选取的胶质瘤患者中,选取荧光定量PCR分析的表达值为参考标准,所得结果降序排列后高于中位数的为LncRNACRNDE高表达,共19例,其他为LncRNACRNDE低表达,共18例。经Kaplan-Meier生存分析,LncRNACRNDE高表达患者的生存期较LncRNACRNDE低表达的患者短,愈后差。差异有统计学意义(P=0.014)。多因素Cox比例风险模型的预后分析发现LncRNACRNDE的相对危险度>1(RR=1.245),表明LncRNACRNDE高表达的患者预后较低表达的患者预后差,LncRNACRNDE的高表达是胶质瘤患者预后风险预测的独立危险因素。
以上研究表明,LncRNACRNDE可作为胶质瘤患者预后的特异性分子标志物。
Claims (1)
1.一种用于胶质瘤患者的预后的实时荧光定量PCR检测试剂盒,其特征在于,
该试剂盒包括:(1)从胶质瘤组织中抽提总RNA所用试剂:RNA稳定溶液、Trizol试剂、三氯甲烷、异丙醇以及无酶水;(2)以总RNA为模板将LncRNACRNDE逆转录为cDNA所用试剂:逆转录缓冲液、三磷酸碱基脱氧核苷酸、RNA酶抑制剂、MMLV逆转录酶以及LncRNACRNDE所用随机引物;(3)将cDNA实时定量PCR所用试剂:LncRNACRNDE实时荧光定量PCR特异性引物、U6snRNA内参特异性PCR引物、实时荧光定量SYBR染料以及无酶水;
LncRNACRNDE实时荧光定量PCR特异性引物:
LncRNACRNDE正向引物5'-CTGCGTGACAACTGAGGA-3',
LncRNACRNDE反向引物5'-GTAGGATGCCACTGGAAAT-3;
U6snRNA内参特异性PCR引物:
正向引物为5′-ATTGGAACGATACAGAGAAGATT-3′,
反向引物为5′-GGAACGCTTCACGAATTTG-3′。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410225220.4A CN103966339B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna crnde的应用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410225220.4A CN103966339B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna crnde的应用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966339A CN103966339A (zh) | 2014-08-06 |
CN103966339B true CN103966339B (zh) | 2016-04-13 |
Family
ID=51236341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410225220.4A Expired - Fee Related CN103966339B (zh) | 2014-05-26 | 2014-05-26 | 长链非编码rna crnde的应用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966339B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107400709A (zh) * | 2017-07-17 | 2017-11-28 | 陈梦麟 | lincRNATUNAR在调节脑神经系统发育中应用 |
CN110714072B (zh) * | 2018-07-12 | 2023-06-13 | 复旦大学附属肿瘤医院 | 一种基于检测LncRNA的癌症预后评估试剂盒 |
CN109609645B (zh) * | 2019-01-22 | 2022-06-21 | 中南大学湘雅医院 | 检测IncRNA LNC_004208表达量的试剂在制备胶质瘤诊断试剂中的应用 |
CN116168843B (zh) * | 2023-01-17 | 2024-04-23 | 重庆医科大学附属儿童医院 | 一种儿童急性髓系白血病预后模型及其构建方法和应用 |
-
2014
- 2014-05-26 CN CN201410225220.4A patent/CN103966339B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
CRNDE:a long non-coding RNA involved in CanceR,Neurobiology,and DEvelopment;Blake C.Ellis,et al;《Frontiers in Genetics》;20121129;第3卷;1-14及附件1 * |
Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients;ATSUSHI KAWAGUCHI,et al;《INTERNATIONAL JOURNAL OF ONCOLOGY》;20121231;721-730页 * |
Long non-coding RNA expression profiles predict clinical phenotypes in glioma;Xiaoqin Zhang,et al;《Neurobiology of Disease》;20121231;1-8页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103966339A (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5792765B2 (ja) | 生検腫瘍組織での遺伝子発現プロファイリング | |
Molloy et al. | The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients | |
AU2012260785B2 (en) | Biomarkers for lung cancer | |
CN103993088B (zh) | 血清Exosomes来源的长链非编码RNA CASC2的应用方法 | |
CN103966338B (zh) | 长链非编码rna rmst的应用方法 | |
CN103966339B (zh) | 长链非编码rna crnde的应用方法 | |
JP2020500515A (ja) | 乳がん患者の予後の予測方法 | |
AU2012342397B2 (en) | A method for predicting responsiveness to a treatment with an EGFR inhibitor | |
CN107475258B (zh) | 一种RNA circEPSTI1及其在三阴乳腺癌上的应用 | |
CA2881389A1 (en) | Methods and kits for screening patients with a cancer | |
CN105431738A (zh) | 胃癌的预后预测模型的建立方法 | |
US20110275089A1 (en) | Methods for predicting survival in metastatic melanoma patients | |
CN108456731A (zh) | 长链非编码rna linc00336作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN101613748A (zh) | 一种检测胰腺癌血清标志物的方法 | |
CN108192974A (zh) | 长链非编码rna linc00842作为生物标志物在制备肺腺癌预后检测制剂中的应用 | |
CN108192976A (zh) | 长链非编码rna linc00336作为生物标志物在制备肺鳞癌预后检测制剂中的应用 | |
CN103981269A (zh) | 长链非编码rna crym-as1的应用方法 | |
CN109295059B (zh) | 一种共价环状闭合单链rna在三阴乳腺癌试剂盒中的应用 | |
EP3202913B1 (en) | A set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival | |
CN102424843A (zh) | 人miR-183/96/182簇的应用及其检测试剂盒 | |
CN105255865A (zh) | Tyms基因表达量荧光定量pcr检测试剂盒及其应用 | |
CN104630377A (zh) | 一种乳腺癌miRNA检测试剂盒及其miRNA的应用 | |
CN108192975A (zh) | 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用 | |
CN110734976B (zh) | 长链非编码rna linc00263在制备肺腺癌预后检测制剂中的应用 | |
CN107641654A (zh) | 胶质瘤预后标志物circ11:66639700|66640123及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160413 |